Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 2:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 7,747 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo; placebo comparator condition Clear all
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose

NCT05136885
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
SLS-005, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Sep 26, 2026, 2:59 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Repurposing Lithium for Parkinson's Disease: a RCT

NCT06339034
View directory record Official record
Conditions
Parkinson Disease
Interventions
Lithium, Placebo
Dietary Supplement · Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
40 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Phase 3 Interventional

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

NCT04777409
View directory record Official record
Conditions
Early Alzheimer´s Disease
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
55 Years to 85 Years
Enrollment
1,840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
107
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Phase 2 Interventional Results available

The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)

NCT01265498
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
Interventions
obeticholic acid, placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
9
States / cities
San Diego, California • San Francisco, California • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Phase 2 Interventional

Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

NCT05141006
View directory record Official record
Conditions
Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
Interventions
BOTOX, Placebo for BOTOX
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
40
States / cities
Homewood, Alabama • Mobile, Alabama • Buena Park, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Sep 26, 2026, 2:59 AM EDT
Terminated Phase 4 Interventional Results available

Use of Sitagliptin to Decrease Microalbuminuria

NCT02048904
View directory record Official record
Conditions
Type 2 Diabetes, Microalbuminuria
Interventions
Sitagliptin, Placebo
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 75 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Combination Probiotic: BB-12 With LGG (Different Doses) in Treating Children With Autism Spectrum Disorder

NCT03514784
View directory record Official record
Conditions
Autism Spectrum Disorder, Gastrointestinal Symptoms
Interventions
BB-12 with LGG (Higher Dose), Placebo, BB-12 with LGG (Lower Dose)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
4 Years to 16 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Phase 2 Interventional Results available

Buspirone in Parkinson's Disease

NCT02803749
View directory record Official record
Conditions
Parkinson Disease, Anxiety
Interventions
Buspirone, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 1, 2020 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Phase 2 Interventional Results available

Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury.

NCT00766038
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Recombinant human Growth Hormone, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Bakersfield, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Phase 3 Interventional

Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD)

NCT02622958
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
PH94B, Placebo
Drug · Other
Lead sponsor
Pherin Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2015 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Phase 2 Interventional Results available

Tivantinib in Treating Patients With Metastatic Prostate Cancer

NCT01519414
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Laboratory Biomarker Analysis, Placebo, Tivantinib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
20
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Sep 26, 2026, 2:59 AM EDT
Active, not recruiting Phase 2 Interventional

High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients

NCT04613206
View directory record Official record
Conditions
Immunization; Infection, Transplantation Infection, Influenza, Solid Organ Transplant
Interventions
High Dose Quadrivalent Inactivated Influenza Vaccine, Standard Dose Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Phase 3 Interventional Results available

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

NCT00917384
View directory record Official record
Conditions
Gastric Cancer, Adenocarcinoma
Interventions
ramucirumab, Placebo, Best Supportive Care (BSC)
Biological · Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
14
States / cities
Bakersfield, California • La Jolla, California • Redlands, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Phase 3 Interventional Results available

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

NCT01696058
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Placebo matching Olodaterol, Olodaterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
94
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 82 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Sep 26, 2026, 2:59 AM EDT
Recruiting Phase 1 Interventional

Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG)

NCT06600178
View directory record Official record
Conditions
Angina Patients With Non-obstructive Coronary Artery Disease, Coronary Microvascular Disease, Coronary Microvascular Dysfunction (CMD)
Interventions
Brenzavvy (bexagliflozin), 20 mg Oral Tablet, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 26, 2026, 2:59 AM EDT
Terminated Phase 3 Interventional

Efficacy and Safety of Ketoprofen Topical Patch 20% in the Treatment of Pain Associated With Shoulder, Elbow or Knee Tendonitis or Bursitis

NCT00426985
View directory record Official record
Conditions
Tendonitis, Bursitis
Interventions
Ketoprofen Topical Patch 20%, Placebo
Drug · Other
Lead sponsor
APR Applied Pharma Research s.a.
Other
Eligibility
18 Years and older
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Phase 2 Interventional Results available

A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

NCT05353985
View directory record Official record
Conditions
Celiac Disease
Interventions
TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar
Drug · Dietary Supplement
Lead sponsor
Takeda
Industry
Eligibility
12 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
61
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Paradise Valley, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Early Phase 1 Interventional

Improving Walking Automaticity in Parkinson's Disease: Levodopa or Donepezil

NCT03599726
View directory record Official record
Conditions
Parkinson Disease
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
50 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 10, 2020 · Synced Sep 26, 2026, 2:59 AM EDT
Active, not recruiting Phase 2 Interventional

The Role of Estrogen in the Neurobiology of Eating Disorders

NCT03740204
View directory record Official record
Conditions
Eating Disorders, Hypoestrogenemia
Interventions
17-β estradiol transdermal patches with cyclic progesterone, Placebo patch and pill
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 35 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease

NCT00446433
View directory record Official record
Conditions
Crohn's Disease
Interventions
CC-5013
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
12 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
5
States / cities
Tucson, Arizona • Anaheim, California • Washington D.C., District of Columbia + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Sep 26, 2026, 2:59 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

NCT05053152
View directory record Official record
Conditions
Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma, Prostate Intraductal Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Fluciclovine F18, Magnetic Resonance Imaging, Placebo Administration, Positron Emission Tomography, PSMA PET Scan, Relugolix, Stereotactic Body Radiation Therapy
Procedure · Other · Drug + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2034
U.S. locations
242
States / cities
Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 192 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 26, 2026, 2:59 AM EDT
Terminated Phase 2 Interventional Results available

Phase IIa L-serine Trial for eAD

NCT03062449
View directory record Official record
Conditions
Alzheimer Disease
Interventions
L-Serine, Placebo Gummy
Drug · Other
Lead sponsor
Aleksandra Stark
Other
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Phase 1 Interventional Results available

Safety Study of TissueGene-C in Degenerative Joint Disease of the Knee

NCT00599248
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
TissueGene-C, Placebo
Biological
Lead sponsor
Kolon TissueGene, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Phase 4 Interventional Results available

A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia

NCT03110315
View directory record Official record
Conditions
Multiple Sclerosis, Fatigue, Insomnia
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Theodore R. Brown, MD MPH
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 26, 2026, 2:59 AM EDT